DDR1 and neoplasm: Collectively, these findings could position DDR1 as a driver of tumor progression and therapy resistance by mediating immune evasion in HNSCC, thereby providing a rationale for targeting DDR1 to restore antitumor immunity and enhance therapeutic outcomes.